May 03, 2011
Tradjenta Approved for Type 2 Diabetes
Tradjenta also produced significant reductions in fasting plasma glucose (FPG) and two-hour post-prandial glucose (PPG) levels compared with placebo, when used as monotherapy or in combination with other antidiabetic agents (eg, metformin, sulfonylurea or pioglitazone). In controlled studies, change from baseline in body weight did not differ significantly between groups when Tradjenta was administered as monotherapy, in combination with metformin or in combination with metformin + a sulfonylurea. Patients treated with Tradjenta exhibited a significant mean decrease from baseline body weight compared to a significant weight gain in patients administered a sulfonylurea (-1.1kg vs. +1.4kg. P<0.0001). Patient weight increased in both the Tradjenta + pioglitazone and placebo + pioglitazone groups during the study with an adjusted mean change from baseline of 2.3kg and 1.2kg, respectively (P=0.0141).
Tradjenta is expected to be available in May 2011 in a 5mg dosage strength.
For more information call (800) 542-6257 or visit www.tradjenta.com.